• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake.相对于进餐时间,在不同时间服用奥利司他对膳食脂肪吸收的影响。
Br J Clin Pharmacol. 1993 Sep;36(3):266-70. doi: 10.1111/j.1365-2125.1993.tb04228.x.
2
Comparison of the inhibition of dietary fat absorption by full versus divided doses of orlistat.全剂量与分剂量奥利司他对膳食脂肪吸收抑制作用的比较。
J Clin Pharmacol. 1994 Nov;34(11):1121-5. doi: 10.1002/j.1552-4604.1994.tb01990.x.
3
Influence of dietary composition on the inhibition of fat absorption by orlistat.饮食成分对奥利司他抑制脂肪吸收的影响。
J Int Med Res. 1994 Sep-Oct;22(5):255-65. doi: 10.1177/030006059402200502.
4
Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers.新型胃肠道脂肪酶抑制剂西替利司他对健康志愿者膳食脂肪吸收的影响
Br J Clin Pharmacol. 2009 Mar;67(3):309-15. doi: 10.1111/j.1365-2125.2008.03311.x. Epub 2008 Sep 19.
5
The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers.健康志愿者中脂肪酶抑制剂奥利司他与乙醇的相互作用。
Eur J Clin Pharmacol. 1998 Nov-Dec;54(9-10):773-7. doi: 10.1007/s002280050550.
6
Pharmacodynamic equivalence of two orlistat capsule formulations in healthy volunteers under fed conditions.两种奥利司他胶囊制剂在进食条件下对健康志愿者的药效学等效性。
Int J Clin Pharmacol Ther. 2008 Jun;46(6):319-26. doi: 10.5414/cpp46319.
7
Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects.脂肪酶抑制可减弱口服脂肪对健康受试者食物摄入量的急性抑制作用。
Br J Nutr. 2003 Nov;90(5):849-52. doi: 10.1079/bjn2003971.
8
The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents.短期(21天)奥利司他治疗对肥胖青少年六种选定常量矿物质和微量矿物质生理平衡的影响。
J Am Coll Nutr. 2003 Oct;22(5):357-62. doi: 10.1080/07315724.2003.10719318.
9
Effects of a lipase inhibitor (Orlistat) on cholecystokinin and appetite in response to a high-fat meal.脂肪酶抑制剂(奥利司他)对高脂餐刺激下胆囊收缩素及食欲的影响。
Int J Obes Relat Metab Disord. 2003 Dec;27(12):1479-85. doi: 10.1038/sj.ijo.0802436.
10
Comparative evaluation of fecal fat excretion induced by orlistat and chitosan.奥利司他与壳聚糖诱导的粪便脂肪排泄的比较评估
Obes Res. 2001 Jun;9(6):364-7. doi: 10.1038/oby.2001.47.

引用本文的文献

1
When fat meets the gut-focus on intestinal lipid handling in metabolic health and disease.当脂肪遇到肠道——关注代谢健康和疾病中的肠道脂质处理。
EMBO Mol Med. 2022 May 9;14(5):e14742. doi: 10.15252/emmm.202114742. Epub 2022 Apr 19.
2
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons.抗肥胖药物研发的局限性:促进饥饿的神经元的关键作用。
Nat Rev Drug Discov. 2012 Sep;11(9):675-91. doi: 10.1038/nrd3739. Epub 2012 Aug 3.
3
Clinical and economic considerations of antiobesity treatment: a review of orlistat.抗肥胖治疗的临床与经济考量:奥利司他综述
Clinicoecon Outcomes Res. 2010;2:63-74. doi: 10.2147/ceor.s5101. Epub 2010 Jul 5.
4
Orlistat: a review of its use in the management of obesity.奥利司他:对其在肥胖管理中应用的综述
Drugs. 1999 Oct;58(4):743-60. doi: 10.2165/00003495-199958040-00015.
5
Orlistat.奥利司他
Drugs. 1998 Aug;56(2):241-9; discussion 250. doi: 10.2165/00003495-199856020-00007.
6
Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study.奥利司他对人体胆囊收缩调节的影响:一项随机双盲安慰剂对照交叉研究。
Dig Dis Sci. 1996 Dec;41(12):2404-8. doi: 10.1007/BF02100135.

本文引用的文献

1
Gastric emptying and secretion of bile acids, cholesterol, and pancreatic enzymes during digestion. Duodenal perfusion studies in healthy subjects.消化过程中胃的排空以及胆汁酸、胆固醇和胰腺酶的分泌。健康受试者的十二指肠灌注研究。
Mayo Clin Proc. 1974 Nov;49(11):851-60.
2
Gastric processing and emptying of fat.胃对脂肪的处理与排空
Gastroenterology. 1986 May;90(5 Pt 1):1176-87. doi: 10.1016/0016-5085(86)90383-5.
3
Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.
Int J Obes. 1987;11 Suppl 3:35-42.
4
Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin.共价抑制剂四氢脂抑素在体外对胰脂肪酶的抑制作用。
Biochem J. 1988 Dec 1;256(2):357-61. doi: 10.1042/bj2560357.
5
Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin.四氢脂抑素的作用机制:天然存在的脂肪酶抑制剂脂抑素的一种衍生物。
Biochim Biophys Acta. 1988 Oct 14;962(3):308-16. doi: 10.1016/0005-2760(88)90260-3.
6
Treating obesity.治疗肥胖症。
BMJ. 1991 Apr 6;302(6780):803-4. doi: 10.1136/bmj.302.6780.803.
7
More on chewing the fat. The good fat and the good cholesterol.
N Engl J Med. 1991 Dec 12;325(24):1740-2. doi: 10.1056/NEJM199112123252411.

相对于进餐时间,在不同时间服用奥利司他对膳食脂肪吸收的影响。

Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake.

作者信息

Hartmann D, Hussain Y, Güzelhan C, Odink J

机构信息

Pharma Clinical Research. F. Hoffmann-La Roche Ltd. Basel, Switzerland.

出版信息

Br J Clin Pharmacol. 1993 Sep;36(3):266-70. doi: 10.1111/j.1365-2125.1993.tb04228.x.

DOI:10.1111/j.1365-2125.1993.tb04228.x
PMID:9114915
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1364649/
Abstract

Orlistat (O) is a potent and selective inhibitor of gastrointestinal lipases. The effect on dietary fat absorption following dosing of O at different times relative to meals was investigated in a placebo (P) controlled study in 24 hospitalized healthy males. After a 5-day run-in, to accustom the subjects to a diet of 2400 kcal and 77 g fat per day and to establish baseline faecal fat excretion, subjects received, in four parallel groups of 6. over 8 days three times daily doses of 80 mg O.P.P (group A) or P. 80 mg O.P (group B) or P.P. 80 mg O (group C) or P.P.P (group D) at mid-meal. 1 h and 2 h after mid-meal respectively. Faeces were collected to measure total fat excretion. The mean (s.d.) of faecal fat in percent of dietary fat, after deduction of pre-treatment faecal fat, was (%) 32.8 (8.1), 34.0 (8.8), 26.9 (4.0) and -1.4 (1.7) in groups A. B. C and D respectively. It was concluded that, within the time period investigated, the pharmacological effect of O is not critically dependent on the time of dosing relative to meals.

摘要

奥利司他(O)是一种强效且具有选择性的胃肠道脂肪酶抑制剂。在一项针对24名住院健康男性的安慰剂(P)对照研究中,研究了在相对于进餐的不同时间给予O后对膳食脂肪吸收的影响。经过5天的导入期,为使受试者适应每天2400千卡热量和77克脂肪的饮食,并建立基线粪便脂肪排泄量,受试者被分为四组,每组6人,在8天内每天三次分别于餐中、餐后1小时和餐后2小时给予80毫克O、P、P(A组)或P、80毫克O、P(B组)或P、P、80毫克O(C组)或P、P、P(D组)。收集粪便以测量总脂肪排泄量。扣除治疗前粪便脂肪后,A、B、C和D组粪便脂肪占膳食脂肪的百分比的平均值(标准差)分别为(%)32.8(8.1)、34.0(8.8)、26.9(4.0)和 -1.4(1.7)。得出的结论是,在所研究的时间段内,O的药理作用并不严格依赖于相对于进餐的给药时间。